Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Chiesi Farmaceutici has agreed to acquire KalVista Pharmaceuticals, a pharmacy business in the United States, for $27.00. KalVista Pharmaceuticals develops specialty medicines and therapies, supporting Chiesi Farmaceutici acquisitions in the healthcare sector. The KalVista Pharmaceuticals acquisition expands Chiesi’s strategic acquisition footprint in pharmacy and strengthens its pipeline and commercial capabilities. The merger acquisition is announced, structured as a strategic acquisition by a corporate buyer, and is expected to follow customary regulatory and closing conditions under the merger agreement.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026